- PF-1355
-
- $30.00
-
2026-04-20
- CAS:1435467-38-1
- Purity: 99.93%
- Supply Ability: 10g
|
| | PF-06281355 Basic information |
| Product Name: | PF-06281355 | | Synonyms: | PF-06281355;PF-1355;PF-06281355 (Free base);2-(6-(2,5-dimethoxyphenyl)-4-oxo-2-thioxo-3,4-dihydropyrimidin-1(2H)-yl)acetamide;6-(2,5-Dimethoxyphenyl)-3,4-dihydro-4-oxo-2-thioxo-1(2H)-pyrimidineacetamide;PF06281355;PF1355;PF 1355;PF-06281355;PF 06281355;1(2H)-Pyrimidineacetamide, 6-(2,5-dimethoxyphenyl)-3,4-dihydro-4-oxo-2-thioxo-;PF-06281355 >=98% (HPLC) | | CAS: | 1435467-38-1 | | MF: | C14H15N3O4S | | MW: | 321.35 | | EINECS: | | | Product Categories: | | | Mol File: | 1435467-38-1.mol |  |
| | PF-06281355 Chemical Properties |
| density | 1.43±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMF: 10mg/mL; DMF:PBS (pH 7.2) (1:1): 0.5mg/mL; DMSO: 10mg/mL; Ethanol: 5mg/mL | | form | A crystalline solid | | pka | 6.93±0.40(Predicted) | | color | White to off-white |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Acute Tox. 4 Oral |
| | PF-06281355 Usage And Synthesis |
| Uses | PF-1355 is a selective 2-thiouracil mechanism-based MPO inhibitor, used for treatment of vasculitic diseases. | | Biological Activity | PF-06281355 (PF-1355) is an orally available, selective and potent mechanism based inhibitor of the myeloperoxidase (MPO) th at reduces plasma MPO activity, vascular edema, neutrophil recruitment, and elevated circulating cytokines. PF-06281355 suppresses albuminuria and chronic renal dysfunction in model of anti-Glomerular Basement Membrane (GBM) disease. | | in vivo | Oral administration of PF-1355 reduces plasma MPO activity, vascular edema, neutrophil recruitment, and elevates circulating cytokines. In a model of anti-glomerular basement membrane disease, formerly known as Goodpasture disease, albuminuria and chronic renal dysfunction are completely suppressed by PF-1355 treatment[1]. | | storage | Store at RT | | References | [1] Zheng W, et al. PF-1355, a mechanism-based myeloperoxidase inhibitor, prevents immune complex vasculitis and anti-glomerular basement membrane glomerulonephritis. J Pharmacol Exp Ther. 2015 May;353(2):288-98 DOI:10.1124/jpet.114.221788 |
| | PF-06281355 Preparation Products And Raw materials |
|